Document:

EX-10.2

 Exhibit 10.2 

SEPARATION AND RELEASE AGREEMENT 

In consideration for the mutual promises and consideration provided both herein and in the Transition Agreement and Release signed
September 5, 2013 (the “Transition Agreement”) between Harrison Dillon (the “Employee”) and Solazyme, Inc. (“Solazyme”) (collectively the “Parties”), the Parties hereby extend by this Separation and
Release Agreement (the “Separation Agreement”) the release and waiver provisions therein to any and all claims that may have arisen between the execution date of the Transition Agreement and the Effective Date of this Separation Agreement,
and to add such releases and waivers as provided herein, expressly including but not limited to a waiver of any federal age related claims under the ADEA. 

1. Consideration. In lieu of all severance compensation and benefits whatsoever, including without limitation any benefits the Employee
may have been entitled to as a result of the Solazyme Executive Severance and Change of Control Plan, or any employment letter or offer letter that the Employee may have entered into with Solazyme (including without limitation the Employment
Agreement dated February 7, 2007 and the Offer Letter dated May 19, 2011), if the Employee (i) signs (on or after the Separation Date (as defined in the Transition Agreement)), dates and returns this fully executed Separation
Agreement to Solazyme within the time set forth in Sections 5 and 6, (ii) allows the releases contained herein to become effective and (iii) otherwise complies with the requirements set forth in this Separation Agreement, the Transition
Agreement, the Consulting Agreement described in Section 1(c) (if executed by the Employee), and the Employee’s Proprietary Information and Inventions Agreement dated October 11, 2004 (the “Confidentiality Agreement”),
Solazyme will provide the Employee with the following as the Employee’s sole severance benefits (the “Severance Benefits”): 
  

	 	a.	Severance Payment. Solazyme will pay to the Employee $312,000 (less the value of the unused paid time off paid to the Employee as of the Separation Date), subject to standard payroll deductions and withholdings.
This severance payment will be paid in a lump sum within ten (10) days after this Separation Agreement becomes “Effective”, as set forth in Section 6, provided the Employee has not materially violated any provisions of this
Separation Agreement, the Transition Agreement, the Consulting Agreement (if executed by the Employee), or the Confidentiality Agreement. 

  

	 	b.	Health Insurance Premium Payments. As an additional severance benefit, so long as the Employee timely elects (and remains eligible for) health benefits continuation pursuant to COBRA, Solazyme will pay the
Employee’s applicable premiums (including spouse or family coverage if the Employee had such coverage on the Separation Date) for such continuation coverage under COBRA (payable as and when such payments become due) during the period commencing
on the Separation Date and ending on the earliest to occur of (a) 24 months following the Separation Date, (b) the termination of the Consulting Agreement, (c) the date upon which the Employee materially breaches this Separation
Agreement, the Transition Agreement, the Consulting Agreement (if executed by the Employee), and/or the Confidentiality Agreement, and (d) the date upon which the Employee and his covered dependents, if any, become eligible for health insurance
coverage through another employer. 

  

					
	Page 1	  	CONFIDENTIAL	  	

	 	c.	Consulting Agreement. As an additional severance benefit, Solazyme will provide the Employee with an opportunity to enter into a Consulting Agreement (the “Consulting Agreement”) in the form provided as
Attachment A. Solazyme will provide an executed copy of the Consulting Agreement to the Employee on the Separation Date. If the Employee chooses to enter into the Consulting Agreement the Employee must do so on or prior to the Effective Date,
at which time Solazyme’s offer to enter into the Consulting Agreement with the Employee shall lapse. If the Employee enters into the Consulting Agreement by the Effective Date, the Employee’s Continuous Service Status (as defined in
Solazyme’s 2004 Equity Incentive Plan and 2011 Equity Incentive Plan (collectively, the “Plans”)) will not be interrupted and equity awarded to the Employee under the Plans and the Employee’s associated Stock Option Agreements
and Restricted Stock Unit Agreements will continue to vest as provided therein. If the Employee does not enter into the Consulting Agreement, the Separation Date is the Employee’s date of termination of employment under the Plans and the
Employee’s associated Stock Option Agreements and Restricted Stock Unit Agreements for vesting purposes. 

  

	 	d.	Breach. In the event that the Employee materially breaches his obligations to Solazyme under this Separation Agreement, the Transition Agreement, the Consulting Agreement (if executed by the Employee), the
Confidentiality Agreement, or as otherwise imposed by law, the Employee agrees that Solazyme will be entitled to terminate the further provision of the Severance Benefits provided in this Section 1 (including without limitation the continued
vesting of the Employee’s equity awards), in addition to seeking any other appropriate relief allowed by law or in equity. 

2. Release. The undersigned Parties expressly acknowledge and agree that the terms of Sections 4, and 6-27 of the Transition Agreement
shall apply equally to this Separation Agreement, shall be construed to be extended through the Effective Date of this Separation Agreement, and are incorporated by reference herein. The Employee agrees that the foregoing consideration represents
settlement in full of all outstanding obligations owed to the Employee by Solazyme and its current and former officers, directors, employees, agents, investors, attorneys, stockholders, administrators, affiliates, benefit plans, plan administrators,
insurers, divisions, and subsidiaries, and predecessor and successor corporations and assigns (collectively, the “Releasees”). Each Party, on his or its own behalf and on behalf of his or its respective heirs, family members, executors,
agents, successors and assigns, hereby and forever releases the other Party and the Employee releases the Releasees from, and agrees not to sue concerning, or in any manner to institute, prosecute, or pursue, any claim, complaint, charge, duty,
obligation, or cause of action relating to any matters of any kind, whether presently known or unknown, suspected or unsuspected, that either Party may possess against the other or that the Employee may possess against any of the Releasees arising
from any omissions, acts, facts, or damages that have occurred up until and including the Effective Date of this Separation Agreement. Notwithstanding the foregoing Solazyme does not release the Employee from any claims resulting from any willful
misconduct by the Employee. As of the date of this Separation Agreement, Solazyme is not aware of any willful misconduct by the Employee. 

3. Payment of Salary and Receipt of All Benefits. The Employee acknowledges and represents that, as of the date this Separation
Agreement is executed, Solazyme has paid or provided all salary, wages, bonuses, accrued vacation/paid time off, leave, housing allowances, relocation costs, interest, severance, outplacement costs, fees, reimbursable expenses, commissions, stock,
stock options, RSUs, vesting, and any and all other benefits and compensation due and owing to the Employee. The Employee further acknowledges and represents that he has received any leave to which he was entitled or that he requested, if any, under
the California Family Rights Act and/or the Family Medical Leave Act, and that he did not sustain any workplace injury, during his employment with Solazyme. 

  
 Page 2 

 4. California Civil Code Section 1542. The Employee acknowledges that he has been
advised to consult with legal counsel and is familiar with the provisions of California Civil Code Section 1542, a statute that otherwise prohibits the release of unknown claims, which provides as follows: 

A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING
THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR. 
 The Employee, being aware of the above
code section, agrees to expressly waive any rights he may have thereunder, as well as under any other statute or common law principles of similar effect. 

5. ADEA Waiver. The Employee further expressly understands and acknowledges that, pursuant to the terms of this Separation Agreement,
he is expressly waiving and releasing any rights he may have under the Age Discrimination in Employment Act of 1967 (“ADEA”), and that this waiver and release is knowing and voluntary. The Employee understands and agrees that this waiver
and release does not apply to any rights or claims that may arise under the ADEA after the date he executes this Separation Agreement. The Employee understands and acknowledges that the consideration given for this waiver and release is in addition
to anything of value to which the Employee was already entitled. The Employee further understands and acknowledges that he has been advised by this writing that: (a) he should consult with an attorney prior to executing this Separation
Agreement; (b) he has twenty-one (21) days from the Separation Date within which to consider this Separation Agreement, by which time Solazyme must receive an executed copy; (c) he has seven (7) days following his execution of
this Separation Agreement to revoke this Separation Agreement, and agrees that any such revocation must be in a writing by email or federal express received by Solazyme by midnight on the seventh day following the Employee’s execution of this
Separation Agreement; (d) this Separation Agreement shall not be effective until after the revocation period has expired; and (e) nothing in this Separation Agreement prevents or precludes the Employee from challenging or seeking a
determination in good faith of the validity of this waiver under the ADEA, nor does it impose any condition precedent, penalties, or costs for doing so, unless specifically authorized by federal law. In the event the Employee signs this Separation
Agreement and returns it to Solazyme in less than the 21-day period identified above (but in any event the Employee agrees not to execute or return this Separation Agreement prior to his separation from employment with Solazyme), the Employee hereby
acknowledges that he has freely and voluntarily chosen to waive the time period allotted for considering this Separation Agreement. The Employee understands and agrees that he executed this Separation Agreement voluntarily, without any duress or
undue influence on the part or behalf of Solazyme or any third party, with the full intent of releasing all of his claims against the Releasees. 

6. Effective Date. The Employee has seven (7) days after he signs this Agreement to revoke it. This Agreement will become
effective on the eighth (8th) day after Employee signed this Agreement, so long as it has not been revoked by the Employee before that date (the “Effective Date”). 

  
 Page 3 

 7. Voluntary Execution. Each Party understands and agrees that he or it executed this
Separation Agreement voluntarily, without any duress or undue influence on the part or behalf of the other Party or any third party, with the full intent of releasing all of his claims against the other Parry and any claim the Employee has against
any of the other Releasees. Each Party acknowledges that: (a) he or it has read this Separation Agreement; (b) he or it has been represented in the preparation, negotiation, and execution of this Separation Agreement by legal counsel of
his own choice or has elected not to retain legal counsel; (c) he or it understands the terms and consequences of this Separation Agreement and of the releases it contains; and (d) he or it is fully aware of the legal and binding effect of
this Separation Agreement. 
 8. Entire Agreement. This Separation Agreement, together with the Transition Agreement, the
Confidentiality Agreement, the Indemnity Agreement, the Option Agreements and any RSU Agreements executed by the Employee with Solazyme, represent the entire agreement and understanding between Solazyme and the Employee concerning the subject matter
of this Agreement and the Employee’s employment with Solazyme, transition of employment, and anticipated separation from employment with Solazyme and the events leading thereto and associated therewith, and supersedes and replaces any and all
prior agreements and understandings concerning the subject matter of this Agreement and the Employee’s relationship with Solazyme, 

9. Governing Law. This Separation Agreement shall be governed by the laws of the State of California, without regard for choice-of-law
provisions. The Parties consent to personal and exclusive jurisdiction and venue in the County of San Mateo in the State of California. 

IN WITNESS WHEREOF, the Parties have executed this Agreement on the respective dates set forth below. 

 

							
		 		 	Harrison Dillon, an individual
			
	Dated: September 30, 2013	 		 	 /s/ Harrison Dillon

		 		 	Harrison Dillon
			
		 		 	SOLAZYME, INC.
				
	Dated: September 30, 2013	 		 	By 	 	/s/ Paul Quinlan
		 		 		 	Name: Paul Quinlan
		 		 		 	Title: General Counsel

  
 Page 4EX-10.3

 Exhibit 10.3 
  

 
 CONSULTING AGREEMENT 

THIS AGREEMENT (“Agreement”), effective as of September 30, 2013 (the “Effective Date”), is by and between
Harrison Dillon, having a mailing address of
                                         
                                         
           (“Consultant”), and Solazyme, Inc., a Delaware corporation having a principal place of business at 225 Gateway Boulevard, South San Francisco, CA 94080 (the
“Company” and together with “Consultant” may be collectively referred to hereunder as the “Parties”). 

WHEREAS, Consultant is in the process of transitioning from being the President of the Company to being a consultant to the Company;
and 
 WHEREAS, the Company desires to utilize the Consulting Services (as defined below) of Consultant in order to continue to
obtain the benefit, experience and ability of Consultant; and 
 WHEREAS, Consultant is willing to render such Consulting Services
and to devote Consultant’s best efforts to the Company upon the terms and conditions hereinafter set forth. 
 NOW, THEREFORE,
in consideration of the foregoing and the mutual promises and covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties do hereby agree as follows: 

1. Scope of Consulting Services; Term. 

(a) The Company hereby engages Consultant to advise and assist the Company with regard to support of general business
activities and intellectual property support, including without limitation, the services set forth in Exhibit A (collectively, the “Consulting Services”). The Company hereby retains Consultant, and Consultant hereby agrees, to
perform assignments, and engage in other work at the direction of the Company related to the Consulting Services. Consultant agrees to perform the Consulting Services on a mutually agreed schedule and location during the Term (defined in
Section 1(c) below). 
 (b) Consultant shall perform the Consulting Services diligently, timely and conscientiously, in
accordance with the highest professional standards and in compliance with all applicable laws and regulations. Consultant shall cooperate with the Company’s personnel and shall not interfere with the conduct of the Company’s business. 

(c) Unless terminated earlier under Section 7, the term of this Agreement (“Term”) shall commence on the
Effective Date and expire on the third anniversary of the Effective Date. 
 2. Consulting Compensation. 

(a) Consulting Fee. The Company shall pay Consultant a fee of $500 per hour during the first 24 months of the Term.
Consultant shall provide, and the Company shall pay for, a minimum of 8 hours per month of Consulting Services during the first 24 months of the Term on mutually convenient dates and times. The Company shall not pay for, or receive, more than 8
hours per month of services during the first 24 months of the Term without the prior written mutual consent of the Company and Consultant. Consultant will also provide a maximum of 8 hours per month of Consulting Services on mutually convenient
dates and times during the final 12 months of the Term in return for the continued vesting of his equity awards from the Company and shall not receive any other fee for such services. If the Company and Consultant mutually consent in writing to have
Consultant provide more than 8 hours per month of Consulting Services during any of the final 12 months of the Term, the Company shall pay Consultant a fee of $500 per hour for each hour in excess of 8 hours up to the maximum amount indicated in the
Company’s and Consultant’s mutual consent. During the Term, Consultant shall on a monthly basis submit to the Company an itemized invoice detailing Consultant’s activities in such month. The Company shall pay the amount due to
Consultant within thirty (30) days of its receipt of such invoice. 

 (b) Expense Reimbursement. The Company shall also reimburse Consultant for
reasonable expenses for airfare and related kinds of travel expenses (e.g., parking), accommodations and food (except for site visits at the Company), incurred during Consultant’s performance of Consulting Services under this Agreement.
Consultant shall obtain prior written consent (email will suffice) from the Company prior to any reimbursable travel under this Agreement. Reimbursement of expenses shall be in accordance with the Company’s written expense reimbursement policy.
Travel time shall not be compensated or included as part of the Consulting Services. Expenses that exceed $1,000 in the aggregate during any given month of the Term shall require the Company’s prior approval (email will suffice). Expenses shall
be reimbursed within thirty (30) days of Consultant’s submission of an invoice setting forth each expense, including the date, amount and purpose for the expense, together with receipts showing payment by Consultant. The Company has no
obligation to reimburse Consultant for expenses that are incurred by Consultant that are not properly documented. 
 3. Independent
Contractor Status. Consultant agrees and acknowledges that Consultant is acting as an independent contractor in performing the Consulting Services and for all other purposes under this Agreement and that the relationship between Consultant and
the Company shall not constitute an employer-employee relationship, partnership, joint venture, or agency. Consultant shall be solely responsible for any and all taxes and any withholding and other self-employment tax obligation with respect to this
Agreement. Consultant agrees that Consultant is not entitled to any of the benefits provided by the Company to the Company employees and that the Company shall not procure, maintain or make payments with respect to any workers’ compensation or
unemployment compensation insurance for or on behalf of Consultant. This provision does not apply to Company’s agreement to provide health insurance premium payments according to Section 1b of the Separation and Release Agreement. 

4. Competitive Activities. Consultant agrees that during the Term he shall not engage in any employment, occupation, consulting or
other business activity that is directly related to, or competitive with, the business in which the Company is now involved, nor will he engage in any other activities that conflict with his obligations to the Company. Consultant will inform the CEO
of the Company in writing (email will suffice) of proposed employment, consulting and business activities of Consultant during the Term, with a reasonable description of his involvement in such activities, if such consulting and/or business activity
is reasonably related to the Company’s Technology Platform (as defined in Exhibit A). The CEO or an individual designated by the CEO shall respond within one week of such notice indicating either (a) that the Company does not believe the
proposed employment, consulting or business activities constitute competitive activities; or (b) that the Company does believe the proposed employment, consulting or business activities constitute competitive activities; or (c) that the
Company desires further information about the proposed employment, consulting or business activities. In the case of (c), a timely response to provision of further information indicating (a) or (b) shall not be unreasonably withheld. Lack
of response to Consultant’s notice within one week shall be deemed agreement that the proposed employment, consulting or business activities do not constitute competitive activities. 

5. Ownership of Intellectual Property and Work Product. All work, reports, writings, ideas, designs, methods, computer software and
data recorded in any form that are created, developed, written, conceived or made by or on behalf of Consultant (whether solely or jointly with others) in rendering Consulting Services hereunder, or in the performance of Consultant’s
obligations under this Agreement, or otherwise related to the Company’s Technology Platform (collectively, “Work Product”) shall be and remain the exclusive property of the Company. The Company shall own all right, title and interest
in and to any and all inventions, discoveries, know-how and other intellectual property, including, without limitation, any improvements thereto, that are conceived, reduced to practice or otherwise made by or on behalf of Consultant (whether solely
or jointly with others) in rendering Consulting Services hereunder, or the performance of Consultant’s obligations under this Agreement, or otherwise directly related to the Company’s Technology Platform and any patent, trade secret or
other intellectual property rights with respect thereto (collectively, “Intellectual Property”). Consultant hereby assigns and transfers to the Company any and all right, title and interest Consultant may have in and to such Intellectual
Property throughout the world. Consultant shall make full disclosure to the Company of Work Product. Consultant agrees that Work Product that is copyrightable subject matter shall be “work made for hire” within the meaning of the copyright
laws of the United States. Consultant shall (i) execute all documents and perform all acts deemed necessary by the Company to evidence the Company’s ownership of the Intellectual Property and Work Product, and (ii) assist the Company
in preparing, prosecuting, obtaining, registering, maintaining, defending and enforcing, at the Company’s expense, at the Company’s discretion and exclusive control, all patents and any foreign equivalents thereof, trademarks, copyrights,
trade secret rights and other proprietary rights in and to the Intellectual Property and Work Product in any and all countries as may be determined by the Company. Consultant shall provide additional assistance to the Company, as necessary, to
protect the Company’s ownership of the Intellectual Property and Work Product in the event of any third party claims related to such ownership. 

  
 2 

 
Consultant hereby appoints the Company as attorney-in-fact for the purpose of executing such documents in Consultant’s name as may be necessary or desirable to carry out the purposes of this
paragraph. Consultant represents, warrants and covenants that neither this Agreement nor Consultant’s Consulting Services hereunder will violate any written agreement, which Consultant has with any other employer, former employer or any other
third party and Consultant will not, in performing the Consulting Services, disclose, violate, infringe or misappropriate any patent, intellectual property, trade secrets or other proprietary information of third parties. 

6. Confidential Information. “Confidential Information” subject to this Agreement is the Company’s information, in
written or verbal form, which comprises or is directly related to technical plans and information, experimental data, financial information, business strategies, grant applications, patent applications, specifications, scientific procedures and
techniques, biological material, intellectual property strategies, trade secrets, general business and commercial information, and other like information. Consultant will protect the Confidential Information provided to Consultant by or on behalf of
the Company from any use, distribution or disclosure except as explicitly permitted by the Company. Consultant will use no less than a high standard of care when protecting Confidential Information and will use Confidential Information solely for
purposes of performing Consulting Services. Notwithstanding the foregoing, Consultant shall have no obligation to the Company with respect to the use, or disclosure to others not party to this Agreement, of such information that: a) prior to
disclosure was known to or in the possession of Consultant as evidenced by its written records; b) is or becomes publicly known during the Term, other than through a breach of Consultant’s obligations hereunder; c) is rightfully received from a
third party who is free to disclose to others without breach of any obligation of non-disclosure; or d) is developed by Consultant independently of any disclosures made under this Agreement as evidenced by its written records, or e) is authorized to
be released by way of express written authorization by the Company. In addition Consultant shall be entitled to disclose Confidential Information to the extent such disclosure is required by applicable law, regulation or bona fide legal process to
be disclosed; provided, however, that (i) Consultant takes all reasonable steps to restrict and maintain the confidentiality of such disclosure and provides reasonable prior written notice to the Company of the requirement to disclose such
information along with the specific disclosure(s) proposed to satisfy such law(s), regulation(s) or legal process(es), and (ii) Confidential Information disclosed pursuant to this Section 6 shall otherwise remain Confidential Information
for the purposes of this Agreement. The obligations set forth in this Section 6 with respect to Confidential Information shall continue in full force and effect for a period of two (2) years after the date of termination or expiration of
this Agreement. Thereafter, Consultant’s obligations under this Section 6 shall survive and continue in effect with respect to Confidential Information that is a trade secret under applicable law. Consultant shall be free to disclose to
others that he is providing, or has provided, Consulting Services. 
 7. Termination. 

(a) This Agreement may be terminated earlier by the Company immediately on written notice to Consultant: 

(i) if Consultant is in breach of his obligations under Section 4 of this Agreement; 

(ii) if Consultant is in material breach of this Agreement; 

(iii) if Consultant is in material breach of the Separation and Release Agreement with the Company dated on or about the date
hereof; and/or 
 (iv) if Consultant is in material breach of the Employee Proprietary Information and Inventions Agreement
with the Company dated October 11, 2004. 
 (b) In the event of termination pursuant to this Section 7 or
expiration of this Agreement, Consultant shall be entitled to receive any consulting fee and expense reimbursement due and payable under this Agreement but not yet paid as of the effective date of termination or expiration and shall be entitled to
all RSUs vested through the termination or expiration of this Agreement and to exercise all stock options vested through the termination or expiration of this Agreement within three months of such termination or expiration. Such payments shall
constitute full and complete settlement of any and all claims of Consultant of every description against the Company. Upon termination or expiration of this Agreement, Consultant shall immediately deliver to the Company all Confidential Information,
Work Product and other property of the Company. 
 (c) Consultant may terminate this Agreement on 45 days notice to the
Company. 

  
 3 

 8. Remedies. All remedies, either under this Agreement or by law or otherwise afforded,
will be cumulative and not alternative. 
 9. Governing Law and Disputes. This Agreement shall be governed by and construed under the
laws of California without reference to its principles of choice of law. 
 10. Entire Agreement; Modifications. This Agreement sets
forth and constitutes the entire agreement and understanding between the parties with respect to the subject matter hereof and all prior agreements, understandings, promises and representations, whether written or oral, with respect thereto are
superseded hereby. No amendment, modification, release or discharge hereof shall be binding upon the parties unless in writing and duly executed by authorized representatives of both Parties. 

11. Severability. If any provision of this Agreement is held to be illegal, invalid or unenforceable under any present or future law,
(a) such provision shall be fully severable, (b) this Agreement shall be construed and enforced as if such illegal, invalid or unenforceable provision had never compromised a part hereof, and (c) the remaining provisions of this
Agreement shall remain in full force and effect. 
 12. Non-Solicitation. During the Term and for a period of one (1) year after
the termination or expiration of this Agreement, Consultant shall not directly or indirectly (i) divert or attempt to divert from the Company (or any affiliate) any business of any kind in which it is engaged, including, without limitation, the
solicitation of or interference with any of its suppliers or customers or (ii) solicit, induce, recruit or encourage any person employed by the Company to leave his or her employment. 

13. Survival. The respective rights and obligations of the parties set forth in Sections 5, 6, 7, 8, 9, 12 and 13 of this Agreement
shall survive the termination or expiration of this Agreement. 
 14. Counterparts. This Agreement may be executed in one or more
counterparts each of which shall be deemed an original and all of which shall together be deemed to constitute one agreement. 
 IN
WITNESS WHEREOF, the Parties have signed this Agreement or have caused this Agreement to be executed by themselves or their duly authorized representatives effective as of the Effective Date. 

 

					
		 	SOLAZYME, INC.	  	HARRISON DILLON
			
		 	 By: /s/ Jonathan Wolfson
	  	/s/ Harrison Dillon
			
		 	 Name: Jonathan Wolfson
	  	
			
		 	 Title: CEO
	  	

  
 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}]]